Please login to the form below

Not currently logged in
Email:
Password:

Nestlé Health Science buys medical device firm

Acquisition of UK's Phagenesis expected to be completed by 2019
Nestlé

Nestlé Health Science is continuing to expand its interests in the broader pharma space with the acquisition of UK medical device firm and dysphagia specialist Phagenesis.

While the financial terms of the deal have not been disclosed, the US food giant's quickly-growing health business will be making an upfront payment for Phagenesis, followed by a series of milestone-based funding.

The staged acquisition is expected to close in 2019 but hinges on the successful completion of the European and US development programmes for Phagenesis' lead product, Phagenyx.

Currently available in Austria, Germany and the UK, Phagenyx is a novel medical device developed by the Manchester-headquartered firm that is designed to restore the neurological control of swallowing.

Instead of merely tackling the symptoms of the condition, Phagenyx establishes a mechanism of action to deliver Pharyngeal Electrical Stimulation (PES) to treat the root cause of dysphagia.

Greg Behar, chief executive at Nestlé Health Science, said: “Dysphagia is a strategic focus for Nestlé Health Science.

“This innovation can bring a new dimension to swallowing rehabilitation that can be transformational from a patient and healthcare professional perspective.”

Dysphagia affects between 29% and 55% of stroke patients, and with approximately 15 million people suffering a stroke each year, the condition has a high prevalence but is often under-diagnosed.

If left untreated, dysphagia can lead to life-threatening complications, including aspiration pneumonia, dehydration and malnutrition, as well as a greatly reduced quality of life.

Reinhard Krickl, Phagenesis' chief executive officer, added: “Nestlé Health Science is the leading global player in dysphagia with capabilities and reach to enable Phagenesis to accelerate the development and deployment of Phagenyx to patients around the world.”

Nestlé has been building its health portfolio steadily over the past few years, and this year entered into research and development partnerships with US-based Seres Therapeutics and Chinese firm Medidata.

Article by
Rebecca Clifford

5th September 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....